Xiaflex Approved by FDA for Treatment of Dupuytren's

Advertisement

Yesterday, the U.S. Food and Drug Administration (FDA) announced its approval of Xiaflex (collagenase clostridium histolyticum) for use in the treatment of Dupuytren’s disease.

Dupuytren's contracture is an abnormal thickening of tough tissue (fibrous layer) underneath the skin of the palm and fingers. It is the thickening of this tissue that can cause the fingers to curl. It can be disabling. Until now there has been no treatment other than surgery. Xiaflex is an injection which will be done in the office.

The FDA's approval of the Xiaflex which is produced by Auxilium Pharmaceuticals Inc follows the September recommendation of a panel of outside medical experts. The panel unanimously voted to support Xiaflex.

It is estimated that 7 million to 14 million Americans have Dupuytren's disease, with men age 50 and older being predominately affected.

Advertisement

Xiaflex is a biologic drug made from the protein product of a living organism. It works by breaking down the excessive buildup of collagen when injected directly into the collagen cord of the hand. It should be administered only by a health care professional experienced with injections of the hand.

A study published in the New England Journal of Medicine looked at 308 patients with joint contractures of 20 degrees or more in a prospective, randomized, double-blind, placebo-controlled, multicenter trial showed significant improvement. More cords that were injected with collagenase than cords injected with placebo met the primary end point (64.0% vs. 6.8%). Overall, the range of motion in the joints was significantly improved after injection with collagenase as compared with placebo (from 43.9 to 80.7 degrees vs. from 45.3 to 49.5 degrees).

The most commonly reported adverse events were localized swelling, pain, bruising, pruritus, and transient regional lymph-node enlargement and tenderness. Three treatment-related serious adverse events were reported: two tendon ruptures and one case of complex regional pain syndrome.

Auxilium intends to market the drug for use not only by hand, orthopedic and other surgeons but also to rheumatologists, nonsurgeons who specialize in arthritis and other joint issues. Physicians would be trained with a video and a training manual, Auxilium said.

Source
U.S. Food and Drug Administration
Auxilium Pharmaceuticals Inc Press Release

Injectable collagenase clostridium histolyticum for Dupuytren's contracture. ; N Engl J Med 361:968 (2009); Lawrence C Hurst et al.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement